Lexaria Bioscience Corp.

10/18/2024 | Press release | Distributed by Public on 10/18/2024 14:43

Proxy Statement Form 8 K

Item 5.08

Shareholder Director Nominations

Further to a recent private placement of share purchase warrants (the "Private Placement Warrants"), as disclosed in a Form 8-K filed on October 16, 2024, the Company is required to seek stockholder approval to such Private Placement Warrants by no later than January 14, 2025. As the date for holding such special meeting is close in time to the anniversary date of the Company's 2024 annual shareholder meeting, it has been determined to hold a joint Annual and Special Meeting of Shareholders on January 14, 2025.

Accordingly, any nominating shareholder or shareholder group must submit their notice on Schedule 14N, of their director nominees for the purposes of including such director nominees in the Company's proxy materials to the attention of Vanessa Carle, Head of Legal at [email protected]by no later than noon Eastern Time on Monday, November 25, 2024.

2